Medicare AdvantageCoverageMedium impact
MA08.040, Telisotuzumab vedotin-tllv (Emrelis™)
Independence Blue Cross·Oncology, Hematology·Pharmacy
Effective date
Oct 1, 2025
We identified it
Jun 19, 2026
Summary
A new Medicare Advantage policy MA08.040 has been established for Telisotuzumab vedotin-tllv (Emrelis™), a specialty oncology medication. This establishes coverage criteria and billing requirements for this new cancer treatment drug effective October 1, 2025.
Action Required
By October 1, 2025: Billing team must review and implement new policy MA08.040 for Telisotuzumab vedotin-tllv (Emrelis™) billing requirements. Verify coverage criteria, prior authorization requirements, and proper HCPCS J-codes for this specialty oncology medication in Medicare Advantage plans. Update billing system with any specific documentation or approval requirements.